Ovarian cancer (OC) is a deadly disease, representing the fifth leading cause of cancer death worldwide. In such a context, the major barrier to improve OC survival is resistance to chemotherapy, including platinum. Indeed, the majority of OC patients respond to initial therapy with tumor cytoreductive surgery and platinum-based chemotherapy, but approximately 70% of advanced stage patients will develop tumor recurrence and eventually succumb to recurrent disease, typically characterized by multiple drug resistance.
RAD6: a new target to overcome platinum resistance in ovarian cancer? / Esposito, Franca. - In: TRANSLATIONAL CANCER RESEARCH. - ISSN 2218-676X. - 6:9(2017), pp. 1476-1479. [10.21037/tcr.2017.11.20]
RAD6: a new target to overcome platinum resistance in ovarian cancer?
Esposito, Franca
2017
Abstract
Ovarian cancer (OC) is a deadly disease, representing the fifth leading cause of cancer death worldwide. In such a context, the major barrier to improve OC survival is resistance to chemotherapy, including platinum. Indeed, the majority of OC patients respond to initial therapy with tumor cytoreductive surgery and platinum-based chemotherapy, but approximately 70% of advanced stage patients will develop tumor recurrence and eventually succumb to recurrent disease, typically characterized by multiple drug resistance.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
